BioWorld Asia

Aug. 14, 2002

Peptor's DiaPep277 Diabetes Product Licensed By Aventis

JERUSALEM, Israel - Peptor Ltd. said July 30 it signed a worldwide agreement with Aventis SA, granting it exclusive rights to develop and commercialize Peptor's DiaPep277 drug for the treatment of autoimmune diabetes. (BioWorld International) Read More

British Biotech Collaborates With GeneSoft In Anti-Infectives Deal

Cureon Raises DKK34M For Antisense DNA Analogue

Evolutec Raises £1.8 Million In Third Round Of Financing

Compugen Uploads Gencarta Database, Extends Pfizer Deal

Other News To Note

Phico Raises £450,000 To Begin Antibiotic Development

Start-Up NascaCell's Platform Speeding Drug Discovery

Pharmos To Study Dexanabinol In Impairment Following Surgery

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

UTRN gene involved in arthrogryposis, study finds

BioWorld Science

Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...

Illustration of glucose in the blood stream

CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

BioWorld Science

Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...